8-K: Rayonier Advanced Materials Secures $67 Million in Green Capital for Biomaterials Expansion

Rayonier Advanced Materials has secured $67 million in green capital through a combination of debt and equity financing to invest in its biomaterials strategy.

Summary

• Rayonier Advanced Materials (RYAM) has raised $67 million in green capital to fund its biomaterials initiatives.
• The financing includes a $37 million secured term loan from French banks and a $30 million preferred equity investment from SWEN Capital Partners.
• The $37 million loan is divided into two tranches: Tranche A of $27.75 million and Tranche B of $9.25 million, with interest rates tied to EURIBOR plus a margin.
• Tranche A has quarterly repayments starting in 2027 and matures in 2031, while Tranche B has a single balloon payment at maturity in 2032.
• SWEN Capital Partners is investing $30 million for a 20% stake in RYAM's new subsidiary, RYAM BioNova SAS, valuing the entity at over $160 million.
• SWEN's investment includes a minimum internal rate of return (IRR) of 16% and a 2x investment multiple, with preferential dividend rights.
• The funds will be used to invest in projects to grow BioNova, including a second-generation bioethanol plant and a prebiotics project.
• RYAM expects these initiatives to generate over $40 million in EBITDA by 2027.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful capital raise and strategic investment in biomaterials, with a clear path to future growth and profitability. The company is taking steps to expand into a growing market.

Positives

• The successful capital raise of $67 million provides significant funding for RYAM's biomaterials strategy.
• The investment from SWEN Capital Partners validates the potential of RYAM BioNova SAS and its projects.
• The expected $40 million in EBITDA by 2027 indicates strong growth potential from the new initiatives.
• The loan terms provide a structured repayment schedule, with the majority of the debt maturing in 2031 and 2032.

Negatives

• The loan interest rates are floating and tied to EURIBOR, which could increase costs if interest rates rise.
• The equity investment from SWEN includes a minimum IRR of 16% and a 2x investment multiple, which could limit future returns for RYAM.

Risks

• The success of the biomaterials projects is dependent on achieving key milestones and market acceptance.
• Fluctuations in EURIBOR could impact the cost of the debt financing.
• The company's ability to achieve the projected $40 million in EBITDA by 2027 is subject to execution risks.

Future Outlook

RYAM expects to drive over $40 million in EBITDA from its biomaterials initiatives by 2027, underscoring its commitment to growth and sustainability.

Management Comments

• De Lyle Bloomquist, President and CEO of RYAM, stated that the formation of BioNova and this latest round of financing are pivotal in their strategic push into biomaterials.
• He also mentioned that with this green capital, they are poised to drive over $40 million in EBITDA from these initiatives in 2027.

Industry Context

This announcement reflects a broader trend of companies investing in sustainable and bio-based materials, as the demand for environmentally friendly products increases. RYAM's move into biomaterials aligns with this trend and positions them to capitalize on the growing market.

Comparison to Industry Standards

• The investment in a second-generation bioethanol plant aligns with industry trends towards advanced biofuels, similar to projects undertaken by companies like POET and Abengoa.
• The focus on prebiotics is also in line with the growing interest in functional foods and health-related ingredients, a market that companies like Cargill and DuPont are also targeting.
• The 16% minimum IRR sought by SWEN is a typical return expectation for private equity investments in growth-stage companies, comparable to other investments in the renewable materials sector.
• The valuation of RYAM BioNova SAS at over $160 million is a significant valuation for a new entity in the biomaterials space, suggesting strong market confidence in the project's potential.

Corporate Governance

Stakeholder Impact

• Shareholders will benefit from the company's strategic expansion into biomaterials and the potential for increased profitability.
• Employees may see new opportunities as the company grows its biomaterials business.
• Customers may have access to new and innovative bio-based products.
• Suppliers may see increased demand for raw materials used in biomaterials production.
• Creditors are provided with a structured repayment schedule for the loan.

Next Steps

• RYAM will use the funds to invest in projects to grow BioNova, including a second-generation bioethanol plant and a prebiotics project.
• Drawdowns are available under the Credit Agreement until the second anniversary of the Credit Agreement, subject to customary conditions precedent.
• Subsequent funding from SWEN is contingent on achievement of key RYAM BioNova SAS project milestones.

Key Dates

Keywords

biomaterials, green capital, bioethanol, prebiotics, RYAM BioNova, SWEN Capital Partners, debt financing, equity investment, EBITDA, cellulose